Overview

Jeffrey Barnes, MD, PhD, is a medical oncologist at the Massachusetts General Hospital Cancer Center's Comprehensive Cutaneous Lymphoma Program and Center for Lymphoma.

Departments

Hematology/Oncology

Centers & Specialties

Cancer Center

Clinical Interests
  • Chronic lymphocytic leukemia (CLL)
  • Cutaneous b-cell lymphoma
  • Cutaneous t-cell lymphoma
  • Hodgkin's lymphoma (also known as Hodgkin's disease)
  • Non-Hodgkin's lymphoma (NHL)
Medical Education
  • MD, PhD, University of Illinois College of Medicine at Urbana-Champaign
  • Residency, Beth Israel Deaconess Medical Center
  • Fellowship, Dana Farber Cancer Institute
Board Certifications
  • Internal Medicine
  • Hematology
  • Medical Oncology
Locations
  • Boston: Massachusetts General Hospital
  • Martha's Vineyard: Martha?s Vineyard Hospital
  • Nantucket: Cottage Hospital
Patient Age Group
Adult
Gender
Male

Edit Profile

Biography

Jeffrey Barnes, MD, PhD is a graduate of the University of Illnois College of Medicine. He completed his residency in Internal Medicine at the Beth Israel Deaconess Medical Center in Boston. He then completed his fellowship in Medical Oncology at the Dana Farber Cancer Institute before joining the faculty at the Massachusetts General Hospital. He is a member of the US Cutaneous Lymphoma Consortium. His research interests focus on the identification and evaluation of novel agents for the treatment of lymphoma.

Edit Profile

Research & Publications

Research Summary
Dr.Barnes performs translational research in lymphoma including clinical trials of novel therapies for the treatment of cutaneous lymphoma, non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia.
Publications

Barnes JA, Abramson JS. Differential Diagnosis and Novel Treatment Strategies for Adult T Cell Leukemia Lymphoma. Oncology. Dec 23;14, p.1267-1270 (2009)

Abramson JS, Hellmann M, Barnes JA, Hammermann P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP. Intravenous methotrexate as central nervous system prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer Jun 8 Epub ahead of print (2010)

Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuburg D, Tomey C, Hochberg EP, Canellos GP, Abramson JS. End of treatment but not interim PET scan predicts outcomes in non-bulky limited stage Hodgkin lymphoma. Ann of Oncology  Oct 15 (2010)

Barnes JA, LaCasce AS, Feng Y, Tomey C, Neuburg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the Addition of Rituximab to CODOX-M/IVAC for Burkitt Lymphoma: A Retrospective Analysis. Ann of Oncology In Feb 21 (2011)

Edit Profile

Contact

Massachusetts General Hospital
55 Fruit Street
Boston MA, 02114
Phone: 617-724-4000
Fax: 617-724-1079

Edit Profile